Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600117368) titled 'Epicardial Injection of Allogeneic Human Pluripotent Stem Cell-derived Cardiomyocytes to Treat Severe Chronic Ischemic Heart Failure' on Jan. 22.
Study Type: Interventional study
Study Design:
Non randomized control
Primary Sponsor: Chinese Academy of Medical Sciences Peking Union Medical College TEDA International Cardiovascular Hospital
Condition:
Severe chronic ischemic heart failure
Intervention:
Dose 1:Epicardial Injection of Allogeneic Human Pluripotent Stem Cell-derived Cardiomyocytes (HiCM-188) at a dose of 50 million HiCM-188 Cells undergoing cor
Dose 3:Epicardial Injection of Allogeneic Human Plur...